Suchergebnisse - "Benboubker, Lotfi"

PubPharm (127)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

enthalten in: EJHaem | 2023

von Richardson, P. | Facon, T. | Venner, C. | +18

3

Multiple Myeloma Spinal Lesion Care : Management of a Primary Bone Malignancy Rather Than a Spinal Metastasis

enthalten in: World neurosurgery | 2023

von Amelot, A. | Terrier, L. | Le Nail, L. | +6

4

Spinal lesions in multiple myeloma : Primary bone tumors with distinct prognostic factors

enthalten in: Surgical oncology | 2023

von Ly, R. | Terrier, L. | Cognacq, G. | +7

5

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

enthalten in: Haematologica | 2023

von Schavgoulidze, A. | Lauwers-Cances, V. | Perrot, A. | +27

6

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS

enthalten in: Blood cancer journal | 2023

von Moreau, P. | Chari, A. | Oriol, A. | +25

7

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS

enthalten in: Blood cancer journal | 07 March 2023

von Moreau, P. | Chari, A. | Oriol, A. | +25

8

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

enthalten in: eJHaem | 2023

von Richardson, P. | Facon, T. | Venner, C. | +18

9

Teclistamab in Relapsed or Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2022

von Moreau, P. | Garfall, A. | van de Donk, N. | +31

CommentIn: N Engl J Med. 2022 Aug 11;387(6):558-561. - PMID 35947712

10

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients : final results of the phase II IFM 2013-06 study

enthalten in: Haematologica | 2022

von Touzeau, C. | Perrot, A. | Roussel, M. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]